Chromosomal Microarray, Tumor, Formalin-Fixed Paraffin-Embedded
Use
Chromosomal microarray (CMA) is used for the genomic characterization of tumors to identify copy number imbalances and regions of loss of heterozygosity. It assists in the diagnosis and classification of malignant neoplasms and evaluates prognosis for patients with malignant tumors. CMA provides a higher diagnostic yield by detecting genetic changes not identifiable by conventional methods like chromosome analysis or FISH, and it helps define the size, breakpoints, and gene content of chromosomal abnormalities. This aids in demonstrating the complexity of abnormalities and assessing potential regions with copy-neutral loss of heterozygosity, common in neoplasia and related to tumor suppressor genes.
Special Instructions
This test must be accompanied by a reason for testing and a pathology report, which can include working drafts or preliminary pathology reports. It is not performed on fresh tissue specimens; if fresh tissue is submitted, a different test (CMAT) will be performed and charged instead. Pathology consultation and additional tests like FISH may be ordered separately at additional costs.
Limitations
The test does not detect balanced chromosome rearrangements (e.g., translocations, inversions), point mutations, small indels, or epigenetic changes. It is limited in detecting mosaicism in samples with less than 20% tumor content and is not suitable for minimal residual disease monitoring. Results may reveal incidental findings not related to the reason for testing.
New York Approved
Methodology
Microarray (SNP Array)
Biomarkers
LOINC Codes
- 94087-4
- 50397-9
- 62356-1
- 62378-5
- 69965-2
- 42349-1
- 31208-2
- 80398-1
- 85069-3
- 48767-8
- 18771-6
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided
Container
Formalin-fixed, paraffin-embedded tumor tissue block